Contact us   |  

"New perspectives in the approach of children with hematological diseases and inborn errors" will be addressed next 5th November at Vall d'Hebron University Hospital

"New perspectives in the approach of children with hematological diseases and inborn errors" will be addressed next 5th November at Vall d'Hebron University Hospital

2019-10-18

The meeting is organized by Vall d'Hebron University Hospital with the endorsement of ERN-EuroBloodNet

Innovative advances for the treatment of children affected by severe hematological diseases and inborn errors have taken place in recent years, as enzymatic replacement tretament in children affected by enzyme defects, new approaches and indications for allogeneic haematopoietic progenitor stem cell transplantation, and the long-expected gene therapy arrival. The correct administration of new atreatments will allow a better clinical care, quality of life and long-term survival of children affected by these pathologies. 

In this context, the meeting “New perspectives in the approach of children with hematological diseases and inborn errors” will take place next 5th November 2019 at Vall d’Hebron University Hospital, with the objective of promoting awareness on the important advances in the field and specifically:

  • Promote indications of the new approaches
  • Increase awareness of the expected results 
  • Understand the circuits for the correct indication and administration of the new treatments

The meeting is organized by the ERN-EuroBloodNet member Vall d’Hebron University Hospital and coordinated by Dr. Cristina Díaz de Heredia (Member representative, Pediatric Oncology and Hematology Service), with the scientific endorsement of ERN-EuroBloodNet and the Spanish Society of Pediatric Hematology and Oncology (SEHOP). The event will count with the participation of Dr. David Beneitez (member substitute representative), and of Dr. María del Mar Mañú Pereira (ERN-EuroBloodNet scientific director), who will present the ERN-Eurobloodnet initiatives for sickle cell disease.

For more information and inscriptions please contact jordi.tejero(ELIMINAR)@mfar.net